Applications Software Technology Acquires Symatrix to Accelerate Global Expansion in Oracle Cloud Services
20.5.2024 15:00:00 EEST | Business Wire | Press release
Applications Software Technology (AST), a leading digital transformation solutions provider, today announced the signing of a definitive agreement for the acquisition of IT and Oracle services provider Symatrix. The acquisition of Symatrix, a leading IT and Oracle services provider in the UK, is a meaningful step in AST’s global expansion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240520063933/en/
“The capabilities of Symatrix complement and broaden AST’s core services and allow us to reach new global markets,” said AST CEO Justin Winter. “Working together we will be able to offer enhanced services to our combined customer base. We’ll continue to deliver high-value solutions that provide measurable value and outcomes for our customers at a global scale.”
Symatrix brings an established UK customer base that strengthens AST’s vertical expertise across numerous industries and provides a platform to further expand in emerging sectors. The deep consulting capabilities of Symatrix will also expand AST’s capabilities across Oracle Cloud Applications, including Supply Chain and Human Capital Management.
“AST is a best-in-class enterprise solutions provider that has developed into a premier consultancy for complex Cloud needs across public and commercial industries,” said Chris Brooks, Symatrix CEO. “Joining forces with AST is a natural progression for Symatrix and allows us to service our customers with even greater resources and technical services.”
“AST and Symatrix represent a powerful combination in Oracle Cloud services,” added Charles Phillips -- Managing Partner for Recognize, Chairman of the Board for AST and former President of Oracle. “The complementary end market exposure helps solidify the businesses’ leadership positions across two continents.”
Following the transition, Chris and the leadership team will remain in their roles with a renewed focus on expanding the UK customer base with a new suite of offerings and delivery geographies from AST.
“At AST, we foster a culture of inclusivity and innovation at every level of our organization,” said Winter. “The Symatrix family embodies these values, and our partnership opens a world of exciting possibilities for our customers and employees.”
About Applications Software Technology (AST) LLC
AST is an award-winning, full-service enterprise solution provider, guiding digital transformation for clients in the Government and Commercial Sectors for more than two decades. Clients look to AST for leadership and assistance in transforming their organizations via software solutions, process engineering, and change management. From cloud technology to legacy on-premises applications, AST’s services encompass all aspects of SaaS, PaaS, and IaaS. AST also offers flexible Managed Services, supporting the needs of over 200 customers around the globe. To learn more, visit www.astcorporation.com.
About Symatrix
Symatrix is a United Kingdom based Oracle HCM, ERP and SCM Cloud Consulting, Application Management and Outsourced Payroll provider. Symatrix works with Public Sector and Commercial clients to innovatively help unlock the endless and exciting possibilities of Oracle Cloud.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240520063933/en/
Contact information
Melissa Sider
Phone: (888) AST-0002
Email: msider@astcorporation.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom